

May 29, 2021

BSE Limited
Department of Corporate Services
Floor 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Kala Ghoda, Fort

Mumbai 400 001

Scrip Code No: 542665

National Stock Exchange of India Limited

Listing Department,

Exchange Plaza,

Bandra Kurla Complex, Bandra (East),

Mumbai - 400 051

Company Symbol: NEOGEN

Sub.: Press Release on the Audited Financial Results of the Company under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the captioned subject, please find enclosed herewith the Press Release on the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2021.

The Audited Financial Results for the quarter and financial year ended March 31, 2021 and the Press Release is also being uploaded on the Company's website at www.neogenchem.com.

Kindly take the same on your record.

Thanking you
Yours faithfully
For Neogen Chemicals Limited

Unnati Kanani Company Secretary and Compliance Officer Membership No. A35131

Encl: As above

CIN No. L24200MH1989PLC050919

E: sales@neogenchem.com
W: www.neogenchem.com

T: +91 22 2549 7300 **F:** +91 22 2549 7399

Press Release

May 29, 2021

Neogen Chemicals maintains growth trajectory despite CoVID-19 related restrictions

Neogen Chemicals Limited (Neogen) recorded an encouraging financial performance during the fourth quarter and full year ended 31st March, 2021. The Company delivered a quarterly revenue from operations of Rs. 93 crore in Q4 FY21 and Rs. 336 crore in FY21. This represents a revenue growth of 13% in Q4 FY21 and 10% in FY21 over the corresponding periods of last year. Robust demand for key products resulted in a better topline performance. This was achieved despite nationwide shutdown impact for first two months of the year and localized restrictions imposed due to second wave of CoVID-19. The Company delivered strong EBITDA performance which was driven by better realisation gains as well as higher operating leverage, as all the plants were running at optimal utilisation levels. Positive performance was delivered even though additional costs were incurred this year on account of CoVID-19 related safety protocols.

Profit after tax (PAT) came in at Rs. 9 crore during the quarter under review as compared to Rs. 7 crore in Q4 FY20. For FY21, profit after tax stood at Rs. 31 crore, up by 9% than Rs. 29 crore in the same period of last year. PAT momentum was facilitated by better operating efficiency and higher revenue growth. Higher depreciation and finance costs linked to CAPEX incurred, and increase in employee costs slowed down the trajectory. Earnings per share in Q4 FY21 increased to Rs. 4.00 per share (Rs. 3.15 per share in Q4 FY20).

Performance at a Glance

	Q4 FY21		FY21	
Revenues	Rs. 93 crore	1 3%	Rs. 336 cr.	1 0%
EBITDA	Rs. 19 crore	1 7%	Rs. 64 crore	O 11%
Profit Before Tax	Rs. 13 crore	1 8%	Rs. 44 crore	O 8%
Profit After Tax	Rs. 9 crore	O 27%	Rs. 31 crore	1 9%

Notes:

- 1. Growth for Q4 FY21 is compared with Q4 FY20
- 2. Growth for FY21 is compared with FY20
- 3. All figures are Consolidated

Commenting on the Q4 & FY21 performance, Mr. Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said:



"It gives me immense pleasure to report that we have maintained our growth momentum in line with the outlook previously highlighted, in a year that's been one of the most difficult in living memory for people and businesses worldwide. During FY21, we have delivered 10% growth in revenues inspite of capacity constraints, expanded margins to 19.1% and increased profits by 9% by driving demand across all key end-user industries while also maintaining supply chain efficiencies. This has been achieved in the backdrop of several widespread/localized restrictions imposed across the country throughout the year.

We are also pleased to inform you that despite these disruptions, our expansion plans have progressed well. We have commissioned equipment related to the production of Organic Products/ Advanced Intermediates at Dahej SEZ facility and production of commercial batches has commenced recently. Following customer validation, product quality assurance and final statutory permissions, we expect to commence commercial production shortly. I would like to thank our entire team at Dahej for their dedication and focused contribution to the implementation of this project in most challenging times. We believe this new, state-of-theart manufacturing infrastructure of international standard will be a gamechanger for Neogen, allowing us to deliver greater value addition through multi-stage processes and complex chemistries. This is the first plant that Neogen has built from scratch and incorporated the most advanced safety features and engineering standards which are required for approvals by Innovators and Global MNC's.

Overall, our business remains ideally positioned to benefit from the long-term value migration witnessed by the Indian specialty chemicals industry. Neogen's market leadership, cost efficient production capabilities and relentless focus on innovation, allows us to capitalize on this opportunity. Overall, we remain well-positioned to drive long-term value for all our stakeholders by executing on our planned initiatives."

Update on brownfield expansion (phase I)

All reactors installed and commenced start up of initial commercial batches

Product quality assurance and customer validation procedures are currently in process. Sales to begin shortly

New world class infrastructure expected to be a game-changer – allowing manufacturing of higher-margin, value-added products – as capability to deliver multi-stage processes and complex chemistries scales up

State-of-the-art facility – driving deeper engagements by leveraging manufacturing excellence and adhering with internationally followed safety & engineering protocols

Will start contributing to revenues from Q2 of FY22; Rs. 450 crore revenue guidance for FY22 remains unchanged

-ENDS-



About Neogen Chemicals Limited

Incorporated in 1989, Neogen Chemicals Ltd. (NSE Code: NEOGEN; BSE Code: 542665) is India's one of the leading manufacturers of Bromine-based and Lithium-based specialty chemicals. Its specialty chemicals product offerings comprise Organic as well as Inorganic chemicals. Its products are used in pharmaceutical and agrochemical intermediates, engineering fluids, electronic chemicals, polymer additives, water treatment, construction and aroma chemicals, flavours and fragrances, specialty polymers, Chemicals and Vapor Absorption Chillers — original-equipment manufacturers. Over the years, Neogen has expanded its range of products and at present, manufactures an extensive range of specialty chemicals which find application across various industries in India and globally. It has a product portfolio of over 224 products.

In addition to manufacturing speciality chemicals, Neogen also undertakes custom synthesis and contract manufacturing where the product is developed and customized primarily for a specific customer, but process know-how and technical specifications are developed inhouse.

The Company operates out of its three manufacturing facilities located in Mahape, Navi Mumbai in Maharashtra, Dahej SEZ, Bharuch and Karakhadi, Vadodara in Gujarat.

For more information, please visit www.neogenchem.com OR contact:

Unnati Kanani

Neogen Chemicals Limited

Tel: +91 22 2549 7300 (Ext: 364) Email: investor@neogenchem.com

Disclaimer: Certain statements in this press release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Neogen Chemicals Limited will not be in any way responsible for any action taken based on such statements and discussions and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.



May 29, 2021

BSE Limited

Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers,

Dalal Street, Kala Ghoda, Fort

Mumbai 400 001

Scrip Code No: 542665

National Stock Exchange of India Limited

Listing Department,

Exchange Plaza,

Bandra Kurla Complex, Bandra (East),

Mumbai - 400 051

Company Symbol: NEOGEN

Sub.: Press Release on the Audited Financial Results of the Company under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the captioned subject, please find enclosed herewith the Press Release on the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2021.

The Audited Financial Results for the quarter and financial year ended March 31, 2021 and the Press Release is also being uploaded on the Company's website at www.neogenchem.com.

Kindly take the same on your record.

Thanking you
Yours faithfully
For Neogen Chemicals Limited

Unnati Kanani Company Secretary and Compliance Officer Membership No. A35131

Encl: As above

CIN No. L24200MH1989PLC050919

E: sales@neogenchem.com
W: www.neogenchem.com

T: +91 22 2549 7300 **F:** +91 22 2549 7399

Press Release

May 29, 2021

Neogen Chemicals maintains growth trajectory despite CoVID-19 related restrictions

Neogen Chemicals Limited (Neogen) recorded an encouraging financial performance during the fourth quarter and full year ended 31st March, 2021. The Company delivered a quarterly revenue from operations of Rs. 93 crore in Q4 FY21 and Rs. 336 crore in FY21. This represents a revenue growth of 13% in Q4 FY21 and 10% in FY21 over the corresponding periods of last year. Robust demand for key products resulted in a better topline performance. This was achieved despite nationwide shutdown impact for first two months of the year and localized restrictions imposed due to second wave of CoVID-19. The Company delivered strong EBITDA performance which was driven by better realisation gains as well as higher operating leverage, as all the plants were running at optimal utilisation levels. Positive performance was delivered even though additional costs were incurred this year on account of CoVID-19 related safety protocols.

Profit after tax (PAT) came in at Rs. 9 crore during the quarter under review as compared to Rs. 7 crore in Q4 FY20. For FY21, profit after tax stood at Rs. 31 crore, up by 9% than Rs. 29 crore in the same period of last year. PAT momentum was facilitated by better operating efficiency and higher revenue growth. Higher depreciation and finance costs linked to CAPEX incurred, and increase in employee costs slowed down the trajectory. Earnings per share in Q4 FY21 increased to Rs. 4.00 per share (Rs. 3.15 per share in Q4 FY20).

Performance at a Glance

	Q4 FY21		FY21	
Revenues	Rs. 93 crore	1 3%	Rs. 336 cr.	1 0%
EBITDA	Rs. 19 crore	1 7%	Rs. 64 crore	O 11%
Profit Before Tax	Rs. 13 crore	1 8%	Rs. 44 crore	O 8%
Profit After Tax	Rs. 9 crore	O 27%	Rs. 31 crore	1 9%

Notes:

- 1. Growth for Q4 FY21 is compared with Q4 FY20
- 2. Growth for FY21 is compared with FY20
- 3. All figures are Consolidated

Commenting on the Q4 & FY21 performance, Mr. Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said:



"It gives me immense pleasure to report that we have maintained our growth momentum in line with the outlook previously highlighted, in a year that's been one of the most difficult in living memory for people and businesses worldwide. During FY21, we have delivered 10% growth in revenues inspite of capacity constraints, expanded margins to 19.1% and increased profits by 9% by driving demand across all key end-user industries while also maintaining supply chain efficiencies. This has been achieved in the backdrop of several widespread/localized restrictions imposed across the country throughout the year.

We are also pleased to inform you that despite these disruptions, our expansion plans have progressed well. We have commissioned equipment related to the production of Organic Products/ Advanced Intermediates at Dahej SEZ facility and production of commercial batches has commenced recently. Following customer validation, product quality assurance and final statutory permissions, we expect to commence commercial production shortly. I would like to thank our entire team at Dahej for their dedication and focused contribution to the implementation of this project in most challenging times. We believe this new, state-of-theart manufacturing infrastructure of international standard will be a gamechanger for Neogen, allowing us to deliver greater value addition through multi-stage processes and complex chemistries. This is the first plant that Neogen has built from scratch and incorporated the most advanced safety features and engineering standards which are required for approvals by Innovators and Global MNC's.

Overall, our business remains ideally positioned to benefit from the long-term value migration witnessed by the Indian specialty chemicals industry. Neogen's market leadership, cost efficient production capabilities and relentless focus on innovation, allows us to capitalize on this opportunity. Overall, we remain well-positioned to drive long-term value for all our stakeholders by executing on our planned initiatives."

Update on brownfield expansion (phase I)

All reactors installed and commenced start up of initial commercial batches

Product quality assurance and customer validation procedures are currently in process. Sales to begin shortly

New world class infrastructure expected to be a game-changer – allowing manufacturing of higher-margin, value-added products – as capability to deliver multi-stage processes and complex chemistries scales up

State-of-the-art facility – driving deeper engagements by leveraging manufacturing excellence and adhering with internationally followed safety & engineering protocols

Will start contributing to revenues from Q2 of FY22; Rs. 450 crore revenue guidance for FY22 remains unchanged

-ENDS-



About Neogen Chemicals Limited

Incorporated in 1989, Neogen Chemicals Ltd. (NSE Code: NEOGEN; BSE Code: 542665) is India's one of the leading manufacturers of Bromine-based and Lithium-based specialty chemicals. Its specialty chemicals product offerings comprise Organic as well as Inorganic chemicals. Its products are used in pharmaceutical and agrochemical intermediates, engineering fluids, electronic chemicals, polymer additives, water treatment, construction and aroma chemicals, flavours and fragrances, specialty polymers, Chemicals and Vapor Absorption Chillers — original-equipment manufacturers. Over the years, Neogen has expanded its range of products and at present, manufactures an extensive range of specialty chemicals which find application across various industries in India and globally. It has a product portfolio of over 224 products.

In addition to manufacturing speciality chemicals, Neogen also undertakes custom synthesis and contract manufacturing where the product is developed and customized primarily for a specific customer, but process know-how and technical specifications are developed inhouse.

The Company operates out of its three manufacturing facilities located in Mahape, Navi Mumbai in Maharashtra, Dahej SEZ, Bharuch and Karakhadi, Vadodara in Gujarat.

For more information, please visit www.neogenchem.com OR contact:

Unnati Kanani

Neogen Chemicals Limited

Tel: +91 22 2549 7300 (Ext: 364) Email: investor@neogenchem.com

Disclaimer: Certain statements in this press release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Neogen Chemicals Limited will not be in any way responsible for any action taken based on such statements and discussions and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.